Theo Outlook
Amgen Inc. is an American multinational biopharmaceutical company focused on molecular biology and biochemistry to provide healthcare based on recombinant DNA technology. For the trailing twelve months ended June 30, 2026, it reported revenue of $38.10 billion, a profit margin of 23%, earnings per share of $16.10, and a market capitalization of $241.81 billion.
Bull case: Quarterly earnings grew 64.9% year over year as of June 30, 2026, with revenue up 9.5% and return on equity of 91.5%. Bear case: The trailing price-to-earnings ratio stands at 27.78 and the forward price-to-earnings at 16.67, while the beta is 0.407.
Main risks include the biopharmaceutical sector's regulatory and competitive pressures. Analysis generated by HeyTheo AI from company and market data. It may be incomplete or inaccurate.
Analysis generated by HeyTheo AI on .
